Noflamen (Meloxicam)

Meloxicam blocks cyclooxygenase enzymes, especially COX‑2, which are essential for producing prostaglandins that mediate inflammation and pain. By lowering prostaglandin levels, the drug diminishes swelling, pain perception, and the inflammatory response in affected tissues.

The exact dose of Noflamen is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Physicians follow approved dosing guidelines but tailor the regimen to each patient.

Safety data for meloxicam in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Meloxicam has a longer half‑life and greater selectivity for COX‑2 compared with ibuprofen, which may allow once‑daily dosing and potentially lower gastrointestinal risk. However, individual response varies, and clinicians consider efficacy, safety profile, comorbidities and cost when choosing an NSAID.

Store Noflamen tablets at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and keep it out of reach of children.

Noflamen is taken orally, usually with a full glass of water. It may be taken with or without food; however, taking it with food can reduce occasional stomach upset. Swallow the tablet whole; do not crush or chew it.

Serious adverse events include gastrointestinal ulceration or bleeding, cardiovascular complications such as heart attack or stroke, severe liver injury, renal failure, life‑threatening skin reactions, and anaphylaxis. Patients should be educated to seek immediate medical attention if they experience any of these symptoms.

Noflamen should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer or bleeding, severe heart failure, uncontrolled hypertension, severe renal or hepatic impairment, and in patients who have had a recent coronary artery bypass graft.